Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no fixed minimum — and no fixed maximum. How long you stay on Mounjaro depends on how your body responds, what your weight-loss goals are, and the clinical judgement of your prescriber. SURMOUNT-1, the pivotal trial published in the New England Journal of Medicine, ran for 72 weeks and found that participants who stopped tirzepatide at that point regained a substantial proportion of the weight they had lost — which is probably the most honest answer to why this question matters so much. Mounjaro is a prescription-only medicine. A GPhC-registered prescriber assesses your individual situation before treatment starts and at every repeat, so duration is always a clinical conversation, never a one-size answer.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The 72-week SURMOUNT-1 trial is the bedrock reference here. Across roughly 2,500 adults with obesity or overweight and at least one weight-related condition, tirzepatide at the highest doses produced average body-weight reductions of around 20–21%, figures that drew wide attention. But the trial also included a withdrawal extension: participants who stopped tirzepatide after the main period regained, on average, more than half that lost weight within a year. That finding matters when you are trying to plan ahead.
It does not mean you must stay on Mounjaro indefinitely. It does mean the question of stopping deserves careful thought, not a calendar-prompted decision. The NICE appraisal of tirzepatide (TA1026) reflects this: it recommends that if someone has not lost at least 5% of their starting weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. That is a response threshold, not a time limit. For people who are responding well, there is no ceiling written into the guidance.
If you are wondering whether your results are on track, our page on how long Mounjaro takes to work walks through the typical timescale week by week, which can help set realistic expectations early on.
Weight regain after stopping GLP-1 medicines is not a failure of willpower. Tirzepatide works by activating GIP and GLP-1 receptors involved in appetite, satiety and the rate at which your stomach empties. When the medicine clears your system, those signals return to their pre-treatment pattern. For many people, that means hunger comes back and the body defends a higher weight set-point. The biology does not reset just because a treatment course has ended.
This is worth sitting with honestly. Many people who reach their target weight feel confident they can maintain without the medicine, and some do, especially when diet, activity and habits have genuinely shifted during treatment. If you are weighing up how long you have to be on Mounjaro, it helps to know that others find the physiological pull back towards their previous weight stronger than they expected. Neither experience is unusual, and neither says anything about character or commitment.
It is also worth knowing that how long you can stay on Mounjaro is a separate question from how long you have to, there is no published upper limit in the SmPC, and long-term continuation is an option if clinical review supports it. The NHS medicines information for tirzepatide on the NHS website is the clearest patient-facing summary of what to expect from ongoing use.
At nume (sorry, at a GPhC-registered pharmacy like ours) duration is not set at the first consultation and left alone. Every repeat requires clinical review. That means your prescriber considers your weight trajectory, any side effects, and our guidance on how long you have to take Mounjaro to see meaningful results before each supply is approved.
There are broadly three situations people arrive at. First, still losing weight and responding well: in this case, continuing is usually appropriate, subject to tolerability. Second, weight loss has plateaued but you have not reached a comfortable stopping point: this is a good moment to discuss whether a dose review or lifestyle adjustment makes sense, our page on not losing weight on tirzepatide covers the practical angles. Third, you have reached your goal weight and want to consider stopping: your prescriber may discuss tapering, a maintenance approach, or planned re-starting if needed later.
If you are thinking about what a private treatment plan might involve financially over time, an honest breakdown is on our Mounjaro price comparison page, including what all-inclusive pricing actually covers when you factor in repeated clinical review and aftercare.
The honest answer to how long you have to stay on Mounjaro is: as long as it takes to achieve and consolidate your goals, subject to ongoing clinical review confirming it remains suitable. For most people in the trials, 72 weeks was a starting point, not the full picture. Duration is a conversation, and it is one our prescribers are well used to having.
If you are ready to start that conversation, check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.